TIP: Tinengotinib In Prostate Cancer

Who Can Participate in the Study?

Age Group
Adults

Study Details

Full Title
A Phase 1b/2 Study Evaluating the Activity of Tinengotinib (TT-00420) in Combination with Androgen Receptor Signaling Inhibitors (ARSIs) in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Principal Investigator
Headshot of Hannah Dzimitrowicz McManus
Assistant Professor of Medicine
Protocol Number
IRB: PRO00116180
NCT: NCT06457919
Phase
Phase I/II
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL